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Objectives This study sought to compare the unrestricted use of everolimus-eluting stents (EES) with sirolimus-eluting
stents (SES) in patients undergoing percutaneous coronary intervention.
Background It is unclear whether there are differences in safety and efficacy between EES and SES during long-term follow-up.
Methods Using propensity score matching, clinical outcome was compared among 1,342 propensity score–matched pairs of pa-
tients treated with EES and SES. The primary outcome was a composite of death, MI, and target vessel revascularization.
Results The median follow-up was 1.5 years with a maximum of 3 years. The primary outcome occurred in 14.9% of
EES- and 18.0% of SES-treated patients up to 3 years (hazard ratio [HR]: 0.83, 95% confidence interval [CI]: 0.68
to 1.00, p  0.056). All-cause mortality (6.0% vs. 6.5%, HR: 0.92, 95% CI: 0.68 to 1.25, p  0.59) was similar,
risks of myocardial infarction (MI) (3.3% vs. 5.0%, HR: 0.62, 95% CI: 0.42 to 0.92, p  0.017), and target vessel
revascularization (7.0% vs. 9.6%, HR: 0.75, 95% CI: 0.57 to 0.99, p  0.039) were lower with EES than SES.
Definite stent thrombosis (ST) (HR: 0.30, 95% CI: 0.12 to 0.75, p  0.01) was less frequent among patients
treated with EES. The reduced rate of MI with EES was explained in part by the lower risk of definite ST and the
corresponding decrease in events associated with ST (HR: 0.25, 95% CI: 0.08 to 0.75, p  0.013).
Conclusions The unrestricted use of EES appears to be associated with improved clinical long-term outcome compared with
SES. Differences in favor of EES are driven in part by a lower risk of MI associated with ST. (J Am Coll Cardiol
2011;57:2143–51) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.01.023Early generation drug-eluting stents (DES) releasing sirolimus
(sirolimus-eluting stents [SES]) or paclitaxel (paclitaxel-
eluting stents [PES]) have reduced the need of repeat
revascularization compared with bare-metal stents (1,2).
Although the rate of mortality and myocardial infarction
(MI) was similar for DES and bare-metal stents (3), very
late stent thrombosis (ST) emerged as a distinct entity
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2010, accepted January 2, 2011.complicating the use of early generation DES (4). More-
over, restenosis still occurs after DES implantation with
evidence of an erosion of antirestenotic efficacy over time
(5). Newer generation DES have been developed with the
aim to improve the safety and efficacy of early generation
devices (6). The newer generation everolimus-eluting stent
(EES) has been shown to improve outcome compared with
PES (7–10). However, data comparing EES with SES are
limited. Since SES have been shown to be superior com-
pared with PES (3,11) as well as with a new-generation
stent eluting zotarolimus from a phosphorylcholine polymer
(12,13), it is relevant to determine whether EES provide
therapeutic benefit over SES. We therefore compared the
outcomes of the unrestricted use of EES and SES in a large,
consecutively enrolled patient population followed for up to
3 years in a propensity-matched analysis.
Methods
Study population and data collection. A total of 1,532 consec-
utive patients were treated with SES (Cypher, Cordis, Miami
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and January 2006, whereas 1,601
consecutive patients underwent
treatment with EES (XIENCE V,
Abbott Vascular, Santa Clara, Cali-
fornia; or PROMUS, Boston Scien-
tific, Natick, Massachusetts) be-
tween November 2006 and March
2009. Patients included in the
SIRTAX (Sirolimus-Eluting Ver-
sus Paclitaxel-Eluting Stents for
Coronary Revascularization) trial
were not eligible in view of man-
dated angiographic follow up (14).
The study complied with the Dec-
laration of Helsinki and was ap-
proved by the institutional ethics
committee at Bern University
Hospital, Switzerland. Patients
gave written informed consent to
be prospectively followed.
All patients were followed up for major adverse cardiac
events using patient-administered postal questionnaires.
Vital status was ascertained from hospital records and
municipal civil registries. All suspected events were
independently adjudicated by a clinical event committee
whose members were unaware of the type of stent
implanted. Baseline clinical and procedural characteris-
tics and all follow-up data were entered into a dedicated
database, held at an academic clinical trials unit (CTU
Bern, Bern University Hospital, Switzerland) responsible
for central data audits and maintenance of the database.
Baseline Characteristics After PS MatchingTable 1 Baseline Characteristics After PS Matching
Before Propensity Score M
EES
(n  1,601)
SES
(n  1,532)
Age, yrs 65.3  11.8 63.3  11.4
Male 1,213 (75.8) 1,193 (77.9)
Body mass index, kg/m2 27.4  4.9 27.4  4.3
Diabetes mellitus 289 (18.1) 270 (17.6)
Insulin-requiring diabetes 84 (29.1) 63 (23.6)
Hypertension 958 (59.8) 831 (54.2)
Hypercholesterolemia 865 (54.0) 766 (50.0)
Current smoking 445 (27.8) 490 (32.0)
Family history of CAD 457 (28.5) 412 (26.9)
Impaired renal function 48 (3.0) 48 (3.1)
Type of indication
Stable angina pectoris 696 (43.5) 688 (44.9)
Unstable angina 115 (7.2) 64 (4.2)
Non–ST-segment elevation MI 527 (32.9) 455 (29.7)
ST-segment elevation MI 261 (16.3) 324 (21.2)
Cardiogenic shock 37 (2.3) 15 (1.0)
Left ventricular ejection
fraction 50%
939 (58.7) 1,012 (66.1)
Abbreviations
and Acronyms
CI  confidence interval
DES  drug-eluting stent(s)
EES  everolimus-eluting
stent(s)
HR  hazard ratio
MI  myocardial infarction
PES  paclitaxel-eluting
stent(s)
PS  propensity score
RR  relative risk
SES  sirolimus-eluting
stent(s)
ST  stent thrombosis
TLR  target lesion
revascularization
TVR  target vessel
revascularizationValues are expressed as mean  SD or n (%). 2-sided p values were calculated using a chi-square test fo
CAD  coronary artery disease; EES  everolimus-eluting stent(s); MI  myocardial infarction; PS  pProcedures. The treatment guidelines, including peripro-
cedural and post-procedural medication regimen, were
performed according to current practice guidelines and
did not change between the inclusion of the first patient
into the SES and inclusion of the last patient into the
EES cohort. All patients received a loading dose of
clopidogrel 300 to 600 mg during the procedure and were
prescribed aspirin once daily lifelong and clopidogrel for
12 months. The use of glycoprotein IIb/IIIa antagonists
was left to the discretion of the operator. Creatinine
kinase (CK), CK-MB, and troponin T were routinely
assessed at baseline and 12 to 24 h after percutaneous
coronary intervention as was a 12-lead electrocardiogram.
Biomarkers were sampled every 6 to 8 h in patients with
signs of ischemia until identification of peak levels.
Definitions. The primary endpoint was the composite of
death, MI, and target vessel revascularization (TVR) up
to a maximum follow-up of 3 years. The definition of
cardiac death included any death due to immediate
cardiac cause, procedure-related deaths, and death of
unknown cause. The diagnosis of Q-wave MI required
ischemic signs or symptoms and new pathological Q
waves in 2 contiguous electrocardiogram leads. In the
absence of Q waves, the diagnosis of MI was based on an
elevation in CK to 2 upper limit of normal and an
levation of CK-MB or troponin to 3 upper limit of
ormal. TVR was defined as repeat revascularization of
ny segment within the entire major coronary vessel proximal
nd distal to a target lesion. Target lesion revascularization
TLR) was defined as revascularization for a stenosis within
he stent or the 5-mm borders adjacent to the stent. ST
g After Propensity Score Matching
p Value
EES
(n  1,342)
SES
(n  1,342) p Value
0.001 63.7  11.6 63.9  11.4 0.62
0.16 1,047 (78.0) 1,040 (77.5) 0.72
0.66 27.4  4.5 27.4  4.2 0.72
0.76 228 (17.0) 235 (17.5) 0.72
0.19 70 (30.7) 55 (23.4) 0.14
0.002 748 (55.7) 746 (55.6) 0.94
0.02 688 (51.3) 713 (53.1) 0.33
0.01 405 (30.2) 422 (31.5) 0.48
0.30 390 (29.1) 363 (27.1) 0.25
0.83 33 (2.5) 45 (3.4) 0.17
0.001 0.009
648 (48.3) 597 (44.5)
34 (2.5) 64 (4.8)
405 (30.2) 419 (31.2)
255 (19.0) 262 (19.5)
0.002 25 (1.9) 14 (1.0) 0.08
0.001 871 (64.9) 842 (62.7) 0.24atchinr categorical variables and using an unpaired t test for continuous variables.
ropensity score; SES  sirolimus-eluting stent(s).
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definitions (15).
Statistical analysis. This was a propensity score (PS)-
matched superiority analysis. Sample size considerations
were based on an updated pooled analysis of trials compar-
ing EES with PES (16), suggesting a relative risk (RR) of
0.60 for the composite of death, MI, or TVR, and a network
analysis comparing SES with PES (3), which suggested a
RR of 0.80 in favor of SES. Taken together, these data
suggested a RR of 0.60/0.80  0.75 in favor of EES. With
an expected crude event rate of 18% at a median
follow-up of 1.5 years with SES, a sample size of 1,400
matched pairs would provide 90% power to detect a RR
of 0.75 in favor of EES. Assuming that 90% of patients
treated with EES could be matched to patients treated
with SES, 1,560 patients treated with EES were neces-
sary for this study.
Procedural Characteristics and Discharge MedicTable 2 Procedural Characteristics and Disc
(n 
Procedural characteristics
Multivessel treatment 3
Number of vessels treated per patient 1.
Number of lesions treated per patient 1.
1 lesion 6
2 lesions 3
3 lesions 1
4 lesions
Target vessel, number of patients
Left main
Left anterior descending 6
Left circumflex 4
Right coronary artery 4
Arterial bypass graft
Saphenous vein graft
Number of stents per patient 2.
Average stent diameter, mm 2.
Total stent length per patient, mm 31.
Maximal inflation pressure, atm 14.
Glycoprotein IIb/IIIa antagonist 3
Medication at discharge
Aspirin 1,3
Clopidogrel 1,3
Oral anticoagulation
Beta-blocker 8
ACE inhibitor 6
AT II inhibitor 1
Calcium antagonist 1
Statin 1,1
Oral antidiabetic agents 1
Insulin
Diuretics 2
Proton pump inhibitor 2
Values are expressed as n (%) or mean SD. 2-sided p values were calc
t test for continuous variables.
ACE  angiotensin-converting enzyme; AT  angiotensin; other abbreviatioWe compared baseline characteristics between patients
treated with EES and SES using a chi-square test for
categorical variables and an unpaired t test for continuous
variables. Then, we used PS matching to account for
differences in baseline characteristics. PS for receiving
EES were estimated using a probit model including age,
gender, and pre-treatment variables associated with stent
selection in the multivariable model at p  0.10 as
ndependent variables (arterial hypertension, hypercho-
esterolemia, clinical manifestation of coronary artery
isease at baseline, and ejection fraction below 50%). An
utomated matching procedure randomly selected a pa-
ient treated with EES and a randomly selected patient
reated with SES from the pool of patients with PS
ithin a caliper of 0.05 on the propensity score. For
ach pair, we ensured equal follow-up times. We used
ox proportional hazards models that accounted for the
s After PS Matchinge Medications After PS Matching
2)
SES
(n  1,342) p Value
.5) 217 (16.2) 0.001
5 1.2 0.4 0.001
0 1.5 0.7 0.001
.5) 843 (62.8)
.4) 361 (26.9)
.8) 116 (8.6)
) 20 (1.5)
) 31 (2.3) 0.004
.3) 659 (49.1) 0.22
.7) 316 (23.6) 0.001
.5) 464 (34.6) 0.20
) 2 (0.2) 0.20
) 41 (3.1) 0.91
1 1.8 0.9 0.001
4 2.9 0.4 0.001
.4 32.7 19.0 0.07
0 14.9 4.2 0.28
.7) 407 (30.3) 0.35
.8) 1,294 (96.6) 0.06
.6) 1,285 (96.4) 0.07
) 27 (2.0) 0.23
.2) 818 (61.4) 0.14
.7) 722 (54.2) 0.20
.3) 213 (16.0) 0.23
) 132 (9.9) 0.32
.3) 1,145 (85.9) 0.06
.4) 135 (10.1) 0.84
) 80 (6.0) 0.91
.5) 249 (18.7) 0.43
.4) 252 (18.9) 0.33
using a chi-square test for categorical variables and using an unpairedationharg
EES
1,34
15 (23
3 0.
8 1.
91 (51
94 (29
72 (12
85 (6.3
58 (4.3
61 (49
12 (30
77 (35
3 (0.2
42 (3.1
0 1.
9 0.
4 19
7 4.
85 (28
12 (97
10 (97
19 (1.4
61 (64
94 (51
92 (14
18 (8.8
18 (83
39 (10
82 (6.1
35 (17
74 (20
ulatedns as in Table 1.
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the 2 stent types. In a sensitivity analysis, we adjusted
procedural characteristics that differed between stent
types in the PS-matched sample at p  0.10. For ST, we
performed landmark analyses according to time points
specified in Academic Research Consortium definitions
(15). Then, we compared the 2 stent types separately on
clinical outcomes associated with ST (defined as events
occurring within a 1-day time window of ST) and not
associated with ST. Finally, we used univariable Cox
Clinical OutcomesTable 3 Clinical Outcomes
EES
(n  1,342)
30 days
Death, all 28 (2.1)
Cardiac death 27 (2.0)
MI 32 (2.4)
Q-wave 3 (0.2)
Non–Q-wave 29 (2.2)
TLR 8 (0.6)
TVR 10 (0.8)
Death or MI 56 (4.2)
Cardiac death or MI 55 (4.1)
Cardiac death, MI, or TLR 61 (4.6)
Cardiac death, MI, or TVR 62 (4.6)
Death, MI, or TLR 62 (4.6)
Death, MI, or TVR 63 (4.7)
1 year
Death, all 60 (4.5)
Cardiac death 42 (3.1)
MI 39 (2.9)
Q-wave 6 (0.5)
Non–Q-wave 33 (2.5)
TLR 48 (3.6)
TVR 65 (4.8)
Death or MI 95 (7.1)
Cardiac death or MI 77 (5.7)
Cardiac death, MI, or TLR 117 (8.7)
Cardiac death, MI, or TVR 131 (9.8)
Death, MI, or TLR 135 (10.1)
Death, MI, or TVR 149 (11.1)
Up to 3 years
Death, all 81 (6.0)
Cardiac death 52 (3.9)
MI 44 (3.3)
Q-wave 6 (0.5)
Non–Q-wave 38 (2.8)
TLR 62 (4.6)
TVR 94 (7.0)
Death or MI 120 (8.9)
Cardiac death or MI 91 (6.8)
Cardiac death, MI, or TLR 144 (10.7)
Cardiac death, MI, or TVR 171 (12.7)
Death, MI, or TLR 173 (12.9)
Death, MI, or TVR 200 (14.9)
Data are n (%). Hazard ratios are from Cox proportional hazard model.
were calculated after a continuity correction of 0.5; p values are 2-sided from
CI  confidence interval; MI  myocardial infarction; TLR  target lesion rmodels to determine whether procedural characteristics
were associated with the primary composite endpoint,
because procedural characteristics were different between
stent types. All p values and 95% confidence intervals
(CIs) are 2-sided.
Results
A total of 3,133 patients (98.7%) completed the last
follow-up (EES  98.7%, SES  98.7%). A comparison of
SES
 1,342)
Hazard Ratio
(95% CI) p Value
37 (2.8) 0.76 (0.46–1.24) 0.27
32 (2.4) 0.84 (0.51–1.41) 0.52
45 (3.4) 0.71 (0.45–1.12) 0.14
9 (0.7) 0.33 (0.09–1.23) 0.10
33 (2.5) 0.88 (0.53–1.45) 0.61
16 (1.2) 0.50 (0.21–1.17) 0.11
22 (1.6) 0.45 (0.22–0.96) 0.039
80 (6.0) 0.70 (0.49–0.98) 0.039
75 (5.6) 0.73 (0.51–1.03) 0.08
81 (6.0) 0.75 (0.54–1.05) 0.09
85 (6.3) 0.73 (0.52–1.01) 0.06
86 (6.4) 0.72 (0.52–0.99) 0.048
90 (6.7) 0.70 (0.51–0.96) 0.029
68 (5.1) 0.87 (0.61–1.23) 0.43
51 (3.8) 0.82 (0.55–1.24) 0.35
55 (4.1) 0.69 (0.45–1.04) 0.08
13 (1.0) 0.50 (0.19–1.33) 0.17
39 (2.9) 0.79 (0.50–1.27) 0.34
59 (4.4) 0.85 (0.58–1.26) 0.43
99 (7.4) 0.68 (0.49–0.93) 0.017
16 (8.6) 0.80 (0.60–1.05) 0.11
00 (7.5) 0.74 (0.55–1.01) 0.06
40 (10.4) 0.84 (0.66–1.08) 0.18
74 (13.0) 0.75 (0.60–0.95) 0.017
56 (11.6) 0.87 (0.69–1.10) 0.26
90 (14.2) 0.78 (0.63–0.97) 0.026
87 (6.5) 0.92 (0.68–1.25) 0.59
59 (4.4) 0.88 (0.61–1.28) 0.51
67 (5.0) 0.62 (0.42–0.92) 0.017
21 (1.6) 0.30 (0.12–0.75) 0.010
42 (3.1) 0.83 (0.53–1.31) 0.43
81 (6.0) 0.80 (0.57–1.12) 0.20
29 (9.6) 0.75 (0.57–0.99) 0.039
45 (10.8) 0.80 (0.63–1.02) 0.08
20 (8.9) 0.74 (0.56–0.97) 0.030
74 (13.0) 0.84 (0.67–1.05) 0.12
17 (16.2) 0.79 (0.64–0.97) 0.025
98 (14.7) 0.88 (0.71–1.09) 0.22
41 (18.0) 0.83 (0.68–1.00) 0.056
s are 2-sided from superiority testing with a Wald test. *Relative risks(n
1
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2
p value
Fisher exact test.
evascularization; TVR  target vessel revascularization.
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thousand three hundred forty-two patients treated with
EES could be matched to 1,342 patients treated with SES.
The median follow-up duration was 1.3 years in both
groups (range 1.0 year to 2.2 years), with an accumulated
2,221 and 2,238 patient-years, respectively. Table 1 shows
re-treatment characteristics at baseline after matching,
hich were comparable between groups. Table 2 presents
rocedural characteristics after matching. Implantation of
ES appeared more complex, with a higher proportion
f patients with multivessel disease and higher number of
esions and vessels treated per patient. Discharge medi-
ations were comparable for both groups, and the median
ength of clopidogrel prescription duration was 12 months
Table 2).
Table 3 presents clinical outcomes up to 3 years. The primary
utcome occurred in 14.9% of EES- and 18.0% of SES-treated
atients up to 3 years (p 0.056) (Fig. 1). The trend in favor of
ES was driven by a significantly lower rate of MI (3.3% vs. 5.0%,
 0.017) and TVR (7.0% vs. 9.6%, p  0.039). Rates of
ll-cause and cardiac mortality were similar, whereas Q-wave MI
Figure 1 Clinical Outcomes in a PS-Matched Cohort of Patients
Cumulative incidence of the primary outcome (A), death (B), myocardial infarction
p values are from 2-sided Wald tests. EES  everolimus-eluting stent(s); PCI  percu0.5% vs. 1.6%, p 0.010) and the composite of cardiac death or
I (6.8% vs. 8.9%, p  0.030) were less frequent with EES.
Table 4 shows associations of procedural characteristics with
the primary outcome stratified by stent type and overall. The
presence of more complex procedural characteristics was gen-
erally associated with worse outcome for both stent types and
overall. A sensitivity analysis of the primary outcome adjusted
for procedural characteristics yielded similar results: HR: 0.78,
95% CI: 0.63 to 0.97, p  0.029.
Results on Academic Research Consortium–defined ST
are summarized in Table 5. Definite ST was less frequent
with EES than SES (0.5% vs. 1.6%, HR: 0.30, 95% CI:
0.12 to 0.75, p  0.010) as was definite or probable ST
(Fig. 2). Clinical outcomes associated with definite ST (left)
and outcomes occurring in the absence of ST (right) are shown
in Figure 3. ST-associated MI (HR: 0.25, 95% CI: 0.08 to
0.75, p  0.013) and TVR (HR: 0.33, 95% CI: 0.12 to 0.92,
p  0.033) were less frequent with EES. These differences
were less pronounced for MI (HR: 0.79, 95% CI: 0.51 to 1.21,
p  0.28) and TVR (HR: 0.84, 95% CI: 0.63 to 1.12, p 
0.24) occurring in the absence of ST (Fig. 3).
o Received EES or SES
C), and target vessel revascularization (TVR) (D) up to 3 years.
s coronary intervention; PS  propensity score; SES  sirolimus-eluting stent(s).Wh
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In this observational, PS-matched study, nested in a pro-
spective registry, the use of EES was associated with a trend
toward a lower risk of the patient-oriented safety and
Association of Procedural CharacteristicsWith Primary Outcome up to 3 Years,Overall and Stra ified by Type of Stent
Table 4
Asso iation of Procedural Characteristics
With Primary Outcome up to 3 Years,
Overall and Stratified by Type of Stent
Procedural Characteristics
Hazard Ratio
(95% CI) p Value
Multivessel treatment, yes vs. no
SES 1.67 (1.24–2.26) 0.001
EES 1.62 (1.20–2.18) 0.001
Overall 1.60 (1.30–1.97) 0.001
Number of vessels treated per patient
(per vessel)
SES 1.69 (1.30–2.21) 0.001
EES 1.55 (1.21–1.98) 0.001
Overall 1.56 (1.31–1.87) 0.001
Number of lesions treated per patient
(per lesion)
SES 1.36 (1.17–1.59) 0.001
EES 1.21 (1.07–1.36) 0.002
Overall 1.23 (1.12–1.34) 0.001
Target vessel, number of patients
Left main, yes vs. no
SES 3.01 (1.76–5.17) 0.001
EES 2.59 (1.63–4.11) 0.001
Overall 2.64 (1.86–3.74) 0.001
Left anterior descending, yes vs. no
SES 1.10 (0.85–1.42) 0.46
EES 0.99 (0.75–1.31) 0.96
Overall 1.05 (0.87–1.27) 0.61
Left circumflex, yes vs. no
SES 0.93 (0.69–1.26) 0.64
EES 1.29 (0.97–1.72) 0.09
Overall 1.08 (0.88–1.33) 0.48
Right coronary artery, yes vs. no
SES 0.89 (0.68–1.16) 0.38
EES 0.82 (0.61–1.10) 0.19
Overall 0.85 (0.70–1.04) 0.12
Arterial bypass graft, yes vs. no
SES —
EES 5.97 (1.48–24.1) 0.01
Overall 2.70 (0.67–10.8) 0.16
Saphenous vein graft, yes vs. no
SES 3.32 (2.10–5.25) 0.001
EES 1.76 (0.96–3.23) 0.07
Overall 2.52 (1.74–3.62) 0.001
Number of stents per patient, yes vs. no
SES 1.33 (1.19–1.50) 0.001
EES 1.18 (1.06–1.32) 0.002
Overall 1.23 (1.13–1.33) 0.001
Average stent diameter, per mm
SES 0.68 (0.47–0.98) 0.04
EES 0.55 (0.36–0.82) 0.004
Overall 0.60 (0.46–0.79) 0.001
Continued in next columnefficacy endpoint of death, MI, and TVR as compared with 1SES during follow-up to 3 years. The risk of MI was
reduced by 38%, and differences in rates of MI were driven
by a 70% reduction in the risk of Q-wave MI.
The results of the present study contribute to a mechanistic
explanation of differences in clinical outcome between EES
and SES. The lower risk of MI with EES was explained in part
by the lower rate of ST (Fig. 2), whereas differences in the risk
of MI occurring in the absence of ST were less pronounced
(Fig. 3). This observation is important because the unrestricted
use of early generation DES was associated with an ongoing
risk of ST during long-term follow-up and stirred a debate
regarding the need of prolonged dual antiplatelet therapy
(17–20). Our long-term data provide novel evidence that ST
beyond 1 year is less frequent with EES compared with SES
(p 0.007), circumventing an important shortcoming of early
eneration DES. The mechanisms underlying the lower risk of
T with EES remain speculative but may be related to the
ower strut thickness with less arterial injury and more rapid
nd complete endothelialization, a biocompatible polymer less
rone to hypersensitivity reactions, and a lower dose of the
ntiproliferative drug.
The risk of TVR was 25% lower with EES than SES, and
he majority of revascularization procedures were related to the
arget lesion. Of note, the risk of TVR associated with ST was
ower with EES, whereas differences between stent types were
ess pronounced for revascularization procedures performed in
he absence of ST. This suggests that differences in revascu-
arization in favor of EES were related in part to a lower
redisposition for ST rather than restenosis. One clinical
egistry and 2 randomized clinical trials have compared EES
ith SES. The X-SEARCH registry (21) showed similar
afety and efficacy outcomes in both EES and SES at 6 months
f follow-up after multivariate adjustment of the 2 sequential
ohorts. The ISAR-TEST 4 (Intracoronary Stenting and
ngiographic Results: Test Efficacy of 3 Limus-Eluting
Tents 4) trial (22) observed a trend toward lower TLR (9.9%
s. 13.5%, p  0.06) and a significant reduction of binary
estenosis at 2 years (12.7% vs. 16.9%, p  0.03) in favor of
ES in the absence of differences for safety endpoints among
ContinuedTable 4 Continued
Procedural Characteristics
Hazard Ratio
(95% CI) p Value
Total stent length per patient, per mm
SES 1.02 (1.01–1.02) 0.001
EES 1.01 (1.01–1.02) 0.001
Overall 1.02 (1.01–1.02) 0.001
Glycoprotein IIb/IIIa antagonist,
yes vs. no
SES 0.89 (0.67–1.18) 0.42
EES 0.87 (0.63–1.19) 0.38
Overall 0.88 (0.72–1.09) 0.25
A value above 1 indicates that the presence of a characteristic was associated with an increased
risk of experiencing the primary composite outcome.
CI  confidence interval; EES  everolimus-eluting stent; SES  sirolimus-eluting stent.,304 patients randomly assigned treatment with EES or SES.
p
h
r
p
m
m
o
t
m
t
n
were calculated after a continuity correction of 0.5; p values are from 2-sided
CI  confidence interval; ST  stent thrombosis; other abbreviations as in
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the Xience V and the Cypher Coronary Stents in Non-selected
Patients With Coronary Heart Disease) trial (23) reported
noninferior outcomes of EES compared with SES in terms of
major adverse cardiac events and TLR at 9 months among
2,774 patients randomly assigned treatment with EES or SES.
The investigators noted a trend toward a lower rate of definite
ST with EES (0.1% vs. 0.7%, HR  0.22, 95% CI: 0.05 to
1.02, p  0.05).
Study limitations. This was not a randomized trial, and
results may be biased. However, we used appropriate PS
matching to ensure comparability of groups. Propensity
scores were defined as the probability to receive EES
conditional on pre-treatment covariates. These covariates
summarize what is known about that patient prior to
treatment. By definition, it is not possible to include
procedural characteristics of the compared interventions in
the PS. Procedural characteristics after PS matching were
different between groups, however. To determine whether
this could explain some of the observed differences between
stent types, we examined the association between markers of
increased procedural complexity and clinical outcome, and
performed a sensitivity analysis adjusted for procedural
characteristics. Our results indicate that, if anything, EES
was put at a disadvantage by the observed higher procedural
complexity (Table 4) and that results remained robustly in
favor of EES after adjusting for procedural characteristics
(p 0.029). Another limitation is the sequential enrollment
eriod. It cannot be excluded that changes in treatment may
ave had a favorable impact on clinical outcome. However,
esults were obtained at a single institution with similar
atient profiles during sequential enrollment periods, thus
inimizing the risk of institutional heterogeneity. Treat-
ent protocols did not change during enrollment, and we
bserved no differences with respect to discharge medica-
ions. The sequential enrollment of SES and EES mini-
izes the potential of confounding by indication because
here was no competition between stent types. Finally, the
SES
1,342)
Hazard Ratio
(95% CI) p Value
(0.8) 0.40 (0.13–1.28) 0.12
(0.4) 0.50 (0.09–2.73) 0.42
(0.7) 0.07 (0–1.16) 0.007
(1.6) 0.30 (0.12–0.75) 0.010
(3.1) 0.74 (0.46–1.17) 0.20
(0.4) 0.50 (0.09–2.73) 0.42
(0.7) 0.07 (0–1.16) 0.007
(4.0) 0.64 (0.41–0.98) 0.041
s are 2-sided from superiority testing with a Wald test. *Relative risks
Fisher exact test.
Table 1.Figure 2 Definite ST of Patients in a PS-Matched Cohort
Who Received EES or SES
Cumulative incidence for definite stent thrombosis (ST) (A), and for the composite
of definite or probable ST (B) up to 3 years. p values are from 2-sided Wald tests.
Dotted line  SES, continuous line  EES. Abbreviations as in Figure 1.Stent ThrombosisTable 5 Stent Thrombosis
EES
(n  1,342) (n 
Definite ST
Early 4 (0.3) 10
Late 2 (0.2) 5
Very late* 0 (0) 7
Overall 6 (0.5) 22
Definite or probable ST
Early 31 (2.3) 42
Late 2 (0.2) 5
Very late* 0 (0) 7
Overall 33 (2.5) 54
Data are n (%). Hazard ratios are from Cox proportional hazard model. p valueumber of pairs successfully matched was lower than as-
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Everolimus- Versus Sirolimus-Eluting Stents May 24, 2011:2143–51sumed in the sample size considerations. This resulted in
somewhat lower power and may explain that we formally
missed the pre-specified alpha level for the primary end-
point. However, the consistent findings in clinical outcomes
Figure 3 Clinical Outcomes According to the Presence or Absence
(Left) Cumulative incidence for death (A), MI (C), and TVR (E) associated with de
occurring in the absence of ST. Dotted line  SES, continuous line  EES. Abbreduring long-term follow-up, with robust reductions in MIand ST, make it unlikely that estimates of safety and efficacy
would differ when studied in a larger population.
Clinical implications. The clinical implications of our
study are 3-fold: First, DES efficacy can be further advanced
Association With Definite ST in a PS-Matched Cohort of Patients
T. (Right) Cumulative incidence for death (B), MI (D), and TVR (F)
s as in Figures 1 and 2.of an
finite S
viationbeyond the level of the previous gold standard of SES
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profile. Second, the phenomenon of very late ST may be less
frequent with EES. Third, our results suggest that the lower
rate of MI was driven at least in part by a lower risk of ST.
This has important implications for the duration of dual
antiplatelet therapy.
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